563 related articles for article (PubMed ID: 17367907)
1. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach.
Nong A; Krishnan K
Regul Toxicol Pharmacol; 2007 Jun; 48(1):93-101. PubMed ID: 17367907
[TBL] [Abstract][Full Text] [Related]
2. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
Pelekis M; Gephart LA; Lerman SE
Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
[TBL] [Abstract][Full Text] [Related]
3. An assessment of the impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants.
Valcke M; Krishnan K
Toxicology; 2011 Aug; 286(1-3):36-47. PubMed ID: 21605617
[TBL] [Abstract][Full Text] [Related]
4. Assessing the impact of the duration and intensity of inhalation exposure on the magnitude of the variability of internal dose metrics in children and adults.
Valcke M; Krishnan K
Inhal Toxicol; 2011 Dec; 23(14):863-77. PubMed ID: 22084919
[TBL] [Abstract][Full Text] [Related]
5. Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals.
Béliveau M; Lipscomb J; Tardif R; Krishnan K
Chem Res Toxicol; 2005 Mar; 18(3):475-85. PubMed ID: 15777087
[TBL] [Abstract][Full Text] [Related]
6. Predicting age-appropriate pharmacokinetics of six volatile organic compounds in the rat utilizing physiologically based pharmacokinetic modeling.
Rodriguez CE; Mahle DA; Gearhart JM; Mattie DR; Lipscomb JC; Cook RS; Barton HA
Toxicol Sci; 2007 Jul; 98(1):43-56. PubMed ID: 17426107
[TBL] [Abstract][Full Text] [Related]
7. A spreadsheet program for modeling quantitative structure-pharmacokinetic relationships for inhaled volatile organics in humans.
Béliveau M; Krishnan K
SAR QSAR Environ Res; 2005; 16(1-2):63-77. PubMed ID: 15844443
[TBL] [Abstract][Full Text] [Related]
8. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs)--application of steady-state PBPK model solutions.
Aylward LL; Kirman CR; Blount BC; Hays SM
Regul Toxicol Pharmacol; 2010 Oct; 58(1):33-44. PubMed ID: 20685286
[TBL] [Abstract][Full Text] [Related]
9. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation.
Thomas RS; Bigelow PL; Keefe TJ; Yang RS
Am Ind Hyg Assoc J; 1996 Jan; 57(1):23-32. PubMed ID: 8588550
[TBL] [Abstract][Full Text] [Related]
10. Molecular structure-based prediction of the steady-state blood concentrations of inhaled organics in rats.
Béliveau M; Krishnan K
Toxicol Mech Methods; 2005; 15(5):361-6. PubMed ID: 20021057
[TBL] [Abstract][Full Text] [Related]
11. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene.
Liao KH; Tan YM; Clewell HJ
Risk Anal; 2007 Oct; 27(5):1223-36. PubMed ID: 18076492
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-property relationships for physiologically based pharmacokinetic modeling of volatile organic chemicals in rats.
Béliveau M; Tardif R; Krishnan K
Toxicol Appl Pharmacol; 2003 Jun; 189(3):221-32. PubMed ID: 12791307
[TBL] [Abstract][Full Text] [Related]
13. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children.
Price K; Haddad S; Krishnan K
J Toxicol Environ Health A; 2003 Mar; 66(5):417-33. PubMed ID: 12712630
[TBL] [Abstract][Full Text] [Related]
14. Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics.
Yoon M; Madden MC; Barton HA
J Toxicol Environ Health A; 2007 Sep; 70(18):1527-41. PubMed ID: 17710613
[TBL] [Abstract][Full Text] [Related]
15. Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform.
Tan YM; Liao KH; Conolly RB; Blount BC; Mason AM; Clewell HJ
J Toxicol Environ Health A; 2006 Sep; 69(18):1727-56. PubMed ID: 16864423
[TBL] [Abstract][Full Text] [Related]
16. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals.
Chiu WA; White P
Risk Anal; 2006 Jun; 26(3):769-80. PubMed ID: 16834633
[TBL] [Abstract][Full Text] [Related]
17. Reconstructing week-long exposures to volatile organic compounds using physiologically based pharmacokinetic models.
Roy A; Georgopoulos PG
J Expo Anal Environ Epidemiol; 1998; 8(3):407-22. PubMed ID: 9679220
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the impact of the exposure route on the human kinetic adjustment factor.
Valcke M; Krishnan K
Regul Toxicol Pharmacol; 2011 Mar; 59(2):258-69. PubMed ID: 20969910
[TBL] [Abstract][Full Text] [Related]
19. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride.
Delic JI; Lilly PD; MacDonald AJ; Loizou GD
Regul Toxicol Pharmacol; 2000 Oct; 32(2):144-55. PubMed ID: 11067771
[TBL] [Abstract][Full Text] [Related]
20. An integrated QSPR-PBPK modelling approach for in vitro-in vivo extrapolation of pharmacokinetics in rats.
Kamgang E; Peyret T; Krishnan K
SAR QSAR Environ Res; 2008; 19(7-8):669-80. PubMed ID: 19061083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
